Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients

<div>Cumulative incidence and unadjusted HR of infections among both groups. (a) All infections. (b) Bacterial infections. (c) Fungal infections. (d) Viral infections other than CMV. (e) CMV infections. EAE: extended alemtuzumab exposure; SIM: standard induction and maintenance therapy.</div>

Canadian Journal of Infectious Diseases and Medical Microbiology

fig1

Figure 1

Figure 1: Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients 

Figure 1 | Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients 